Eli Lilly CEO Dave Ricks has expressed a willingness to support national security efforts by helping secure the U.S. supply of essential medicines, as the pharmaceutical industry braces for potential drug tariffs under a Section 232 investigation. This investigation is assessing whether the reliance on imported pharmaceuticals, particularly older generics, poses a threat to national security. While the investigation’s outcome remains uncertain, tariffs could soon be imposed on drugs largely manufactured abroad, especially in countries like India and China.
Ricks acknowledged the legitimacy of concerns surrounding the accessibility of older essential medicines, which make up about 90% of prescriptions in the U.S. and include vital hospital drugs like antibiotics and vasopressors. He noted that the U.S. lost much of its domestic production capacity for these inexpensive but complex medicines due to cost pressures and unfavorable policies. However, he remains unconvinced that tariffs are the most effective response to this issue.
Instead of relying on import duties, Ricks proposed collaborative solutions, saying Eli Lilly is open to working with national security and government stakeholders in the event of a pharmaceutical crisis. He emphasized the company’s manufacturing capacity and its ability to contribute meaningfully to restoring drug supply chains within the U.S.
The CEO also questioned whether tariffs are necessary, suggesting that the mere threat of such measures is already encouraging pharmaceutical companies to reinvest in domestic production. As evidence of this shift, Eli Lilly recently announced a $27 billion commitment to construct four new manufacturing sites in the U.S. This expansion aligns with a broader industry trend toward reshoring critical supply chains amid increasing geopolitical and economic uncertainty.
Ricks also stressed the importance of creating lasting economic incentives to support this transition. He advocated for a permanent domestic corporate tax rate of 15%, arguing that such a policy would make the U.S. a more attractive location for pharmaceutical manufacturing. Many drugmakers previously offshored production to low-tax countries like Ireland, Singapore, and Switzerland. By lowering tax rates at home, he believes the U.S. can encourage companies to return and stay.
While some executives remain cautious, citing ongoing uncertainty as a deterrent to investment, Ricks sees the reshoring trend as already underway. He remains skeptical that formal tariffs will be needed if industry-led efforts and economic incentives continue to drive manufacturing back to the U.S.
READ MORE: